GlycoMimetics (NASDAQ:GLYC) Rating Reiterated by HC Wainwright

GlycoMimetics (NASDAQ:GLYC)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a report issued on Monday, MarketBeat Ratings reports.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. Capital One Financial reiterated an “overweight” rating on shares of GlycoMimetics in a research note on Thursday, February 22nd.

GlycoMimetics Stock Down 3.2 %

GlycoMimetics stock opened at $0.31 on Monday. The firm has a 50 day moving average price of $2.42 and a 200-day moving average price of $2.33. GlycoMimetics has a twelve month low of $0.27 and a twelve month high of $3.53. The company has a market capitalization of $19.68 million, a P/E ratio of -0.53 and a beta of 2.30.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings data on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.01 million for the quarter. Equities analysts expect that GlycoMimetics will post -0.54 EPS for the current fiscal year.

Institutional Trading of GlycoMimetics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisor OS LLC purchased a new position in GlycoMimetics during the fourth quarter valued at approximately $238,000. MJP Associates Inc. ADV purchased a new position in shares of GlycoMimetics during the 4th quarter valued at $238,000. Finally, Acuta Capital Partners LLC bought a new position in shares of GlycoMimetics in the third quarter worth $41,000. 75.19% of the stock is currently owned by institutional investors.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.